SCHEMBL4278071

SCHEMBL4278071

CC(C)COc1cc(OCC(C)C)cc(C(=O)c2ccc(OCC(C)C)c(CCC(=O)O)c2)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 0.84
JUN P05412 2/20 0.84
LTB4R Q15722 4/20 0.51
ELANE P08246 1/20 0.49
ALDH1A1 P00352 2/20 0.46
HIF1A Q16665 1/20 0.46
LTB4R2 Q9NPC1 3/20 0.44
DRD3 P35462 1/20 0.44
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
RARA P10276 1/20 0.42
RARB P10826 1/20 0.42
RARG P13631 1/20 0.42
GCK P35557 1/20 0.42
CSF3R Q99062 1/20 0.39
NR1H4 Q96RI1 3/20 0.39
FFAR1 O14842 1/20 0.38
PTGER1 P34995 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31191805 0.92 FOS (1.00) FOSJUNLTB4RELANEALDH1A1
SCHEMBL1527292 0.92 FOS (1.00) FOSJUNLTB4RELANEALDH1A1
SCHEMBL4281307 0.89 FOS (0.82) FOSJUNLTB4RELANEALDH1A1
SCHEMBL4277644 0.86 FOS (0.64) FOSJUNLTB4RALDH1A1HIF1A
SCHEMBL4282700 0.86 JUN (0.81) FOSJUNLTB4RELANEALDH1A1
SCHEMBL4276620 0.86 JUN (0.81) FOSJUNLTB4RELANEALDH1A1
SCHEMBL4279563 0.83 JUN (0.76) FOSJUNLTB4RELANEALDH1A1
SCHEMBL13442883 0.82 FOS (0.82) FOSJUNLTB4RELANEALDH1A1
SCHEMBL2968731 0.82 JUN (0.70) FOSJUNLTB4RELANEALDH1A1
SCHEMBL4288990 0.81 JUN (0.73) FOSJUNLTB4RELANEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 US disclosed
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 US disclosed
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 US disclosed
CN-1325376-A Novel compound and medical use thereof TOYAMA CHEMICAL CO LTD (JP) 2001-12-05 CN disclosed
EP-1127869-A1 NOVEL COMPOUNDS AND MEDICINAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2001-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF SP1, AP1G1, AP1M1 FOS 63/4885JUN 20/4885LTB4R 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.